Navigating Novel Terrain in Anemia of Chronic Kidney Disease: A Patient-centric Review of Disease State, Current Chasms in Care, and the Future Promise of HIF-PH Inhibition
Released On
October 6, 2022
Expires On
October 23, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Cardiology, Endocrinology, Hematology-Oncology, Nephrology, Pharmacy, Primary Care
Topic(s)
Cardiovascular Disease, Diabetes, Pharmacology
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Creative Educational Concepts.
This activity is supported by an independent educational grant from GlaxoSmithKline.
Credit Available
- Physicians — 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
- Pharmacists — 1.0 Contact Hours (.10 CEUs)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of nephrologists, hematologists, primary care physicians, internists, hospitalists, endocrinologists, cardiologists, nurses, nurse practitioners, physician assistants, and pharmacists.
Program Overview
To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs. However, HIF-PHIs place in therapy has not yet been fully elucidated. Here, join the interprofessional team of Dr. Ajay Singh, Dr. Jane Davis, and Dr. Calvin Meaney as they explore an incisive review of current CKD-anemia treatment and diagnostic challenges, as well as the evidentiary base for HIF-PHI utilization in CKD-anemia that establishes context for the future of these agents. In conclusion, a practical discussion of real-world patient case scenarios will be presented, to provide learners with context of the multiple comorbidities, complexities, diagnostic challenges, and barriers to appropriate treatment of CKD-anemia.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Review the prevalence and pathophysiology of anemia of CKD, emphasizing the multifaceted, patient-centric burden of disease.
- Evaluate potential causes of CKD-anemia underdiagnosis and undertreatment, and propose adaptive, evidence-based solutions to optimize care.
- Appraise current clinical controversies in the management of CKD-anemia, highlighting the safety concerns posed by ESAs, and discuss how these challenges have prompted the need for novel therapeutic approaches.
- Examine hypoxia-inducible factor (HIF) as a key pathophysiologic component and a novel treatment target in CKD-anemia.
- Summarize the expanding clinical trial evidentiary base and regulatory landscape for HIF-PH inhibitors in CKD-anemia management.
- Use a practical, case-based format to design individualized and multidisciplinary treatment plans for patients with CKD-anemia that are safe, effective, and promote equitable solutions to healthcare disparities.
Faculty
Ajay K. Singh, MBBS, FRCP, MBA (Activity Chair)
Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) program
Harvard Medical School
Physician, Renal Division
Brigham and Women’s Hospital/ Dana Farber Cancer Institute
Boston, Massachusetts
Jane S Davis, DNP, CRNP
Nephrology
University of Alabama at Birmingham
Birmingham, Alabama
Calvin J. Meaney, PharmD, BCPS
Clinical Associate Professor and Vice Chair for Research
Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
University at Buffalo
Buffalo, New York
Accreditation Statement
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. All activities will be fully compliant with ACCME Standards for Commercial Support, as well as AMA, FDA, and PhRMA/OIG guidelines.
Physician Credit Designation
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy Credit Designation
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-013-H01-P).
Nursing Continuing Education
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Disclosures of Conflicts of Interest
Planner/Faculty
- Ajay K. Singh, MBBS, FRCP, MBA
-
- Employment/Salary: Harvard University Medical School, Brigham and Women's Hospital
- Educational Grant: GlaxoSmithKline
- Consultant: Bayer, GlaxoSmithKline, Nephrology Times, and Zydus.
Faculty
- Jane S. Davis, DNP, CRNP
-
- Employment: University of Alabama at Birmingham
- Speakers' Bureau: Bayer
- Calvin J. Meaney, PharmD, BCPS
-
- Employment/Salary: Wolters Kluwer
- Consultant: GlaxoSmithKline, Vifor Pharma
Peer Reviewer
Erin Spencer, PharmD - has no relevant financial relationships to disclose in relation to the content of this activityCEC Staff/Planners
Susan H. Gitzinger, PharmD, MPA - has no relevant financial relationships to disclose in relation to the content of this activityJessica Hall - has no relevant financial relationships to disclose in relation to the content of this activity
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Successfully complete the post-test.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
It is the policy of Creative Educational Concepts LLC (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of the date this activity launched. All materials contained herein reflect the views of the faculty and not those of Creative Educational Concepts LLC or the commercial supporter(s).
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: Contact info@ceconcepts.com.